In addition, Glo1 overexpression combats RV fibrosis and echocardiography and closed-chest pressure volume loop analysis show AAV-Glo1 treatment enhances RV systolic and diastolic function without significantly altering PAH severity. The gene discussed is GLO1; the disease is pulmonary arterial hypertension.